双核铜复合体与肝脏药物代谢细胞染色体P450的相互作用
Alena Špičáková1, Zuzana Horáčková2, Pavel Kopel3
1Department of Pharmacology, Faculty of Medicine, Palacký University Olomouc, Hněvotínská 3, 779 00 Olomouc, Czech Republic.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2024
概括
研究了两种新的铜 (II) 复合物,以了解它们作为抗菌药物的潜力. 它们可能抑制人类肝脏的关键酶 (细胞染色体P450),表明可能的药物相互作用,并建议局部应用.
科学领域:
- 协调化学 协调化学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 合成了带有二碳酸盐桥梁的铜 (II) 复合物.
- 这些复合物具有甲基二乙二胺 (pmdien) 连接体和不同的二碳酸盐桥梁 (酸或3,3'-二二二酸).
研究的目的:
- 研究两种新型铜 (II) 混合联结体复合体对人类肝脏药物代谢酶的抑制作用.
- 评估药物相互作用的潜力,当这些复杂物与通过细胞染色体P450 (CYP) 代谢的其他药物同时使用时.
主要方法:
- 两种铜 (II) 混合联结体复合物的合成和表征.
- 在体外研究复合物对特定的人类细胞染色体P450酶 (CYP2C8,CYP2C19,CYP3A4) 的抑制活性.
主要成果:
- 铜 (II) 复合物对人类肝脏中关键的药物代谢酶,特别是CYP2C8,CYP2C19和CYP3A4.4具有抑制作用.
- 结果表明,与这些酶代谢的同时使用的药物之间可能存在药物相互作用.
结论:
- 这项研究强调了由于这些铜 (II) 复合物的抑制作用对细胞染色体P450酶造成不良药物相互作用的可能性.
- 局部应用这些潜在的抗微生物药物可能是一个更安全的给药途径,以减轻相互作用风险.
相关概念视频
Drug Metabolism: Phase I Reactions
3.2K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.2K
Hepatic Drug Excretion: Enterohepatic Cycling
1.1K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.1K
Drug Metabolism: Phase II Reactions
3.7K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.7K
Phase II Reactions: Miscellaneous Conjugation Reactions
48
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
48
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Hepatic Drug Clearance: Role of Transporters
44
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
44


